FDA accepts Genentech’s Gazyva application for SLE, what it means for lupus treatment
FDA accepts Genentech’s Gazyva filing for systemic lupus erythematosus. Read what the ALLEGORY data could mean for lupus treatment in 2026.
Could Hinge Bio, Inc. unlock a new class of lupus B-cell depletion therapies?
Hinge Bio, Inc. doses first subjects in HB2198 Phase 1 trial. Discover what this could mean for lupus treatment and next-generation immune reset therapies.
Gazyva’s ALLEGORY data: what the SRI-4 and DORIS remission outcomes mean for lupus care
Genentech’s obinutuzumab met all ALLEGORY phase III endpoints in SLE. What the remission and flare data mean for lupus treatment strategy.